Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CGRP antibody
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Anti-CGRP antibodies are a class of monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway, which plays a central role in the transmission of pain and the development of neurogenic inflammation. These biologics either bind to the CGRP ligand itself or block the CGRP receptor, effectively inhibiting the vasodilatory and pro-inflammatory effects of the neuropeptide. Originally developed and approved for the prevention of migraine (e.g., erenumab, fremanezumab, galcanezumab, and eptinezumab), these antibodies are now being investigated for other conditions characterized by headache and elevated intracranial pressure. A notable clinical trial sponsored by Rigshospitalet is evaluating the efficacy of anti-CGRP antibody treatment in preventing chronic headaches in patients with idiopathic intracranial hypertension (IIH).
- Other names
- anti-CGRP antibodyCGRP inhibitorCGRP monoclonal antibody
02
Targets
Calcitonin gene-related peptide type 1 receptorCGRP (Calcitonin gene-related peptide)FcγR/C1q (Fc gamma receptors and complement component C1q)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on anti-CGRP antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CGRP antibody.